how-msi-is-putting-molecular-data-into-tissue-context-for-quicker-better-and-more-reliable-pharmaceutical-r-d

How MSI is Putting Molecular Data into Tissue Context for Quicker, Better and more Reliable Pharmaceutical R&D

25 years after its introduction, Mass Spectrometry Imaging (MSI) has become a widely used technology in the pharmaceutical research & development to understand the complexity of biological events happening within tissue. Direct molecular imaging is playing a pivotal role in modern drug development by providing PK, PD, safety and target engagement information, crucial for decision making. Most pharmaceutical companies and many CROs have integrated the MSI toolbox to their workflows in combination with digital pathology and highly multiplexing immunohistochemistry. This webinar will describe how MSI is supporting AstraZeneca portfolio through different example of applications dealing with cancer research and respiratory diseases as well as new translational model development.

Conference animated by :

David Bonnel

David Bonnel

Executive Director,

Imabiotech

Gregory Hamm

Gregory Hamm

Associate Principal Scientist,

AstraZeneca

Tuesday, September 15th 2020

from 16:30 to 17:30

(Europe/Paris)

161 subscribers | 60 mins

Subscription 100% free

Email notifications before the webinar

Chat zone to ask your questions

Replay until April 2, 2021